Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 14/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566011 | 0.87 | CYP17A1 (0.40) | CYP17A1CYP26A1CYP3A4 | |
| SCHEMBL8230585 | 0.82 | CYP17A1 (0.50) | CYP17A1CYP11B1CYP11B2CYP26A1CYP3A4 | |
| SCHEMBL8229870 | 0.78 | CYP17A1 (0.52) | CYP17A1CYP11B1CYP11B2CYP26A1CYP3A4 | |
| SCHEMBL4056699 | 0.78 | CYP17A1 (0.57) | CYP17A1CYP11B1CYP11B2CYP26A1 | |
| SCHEMBL9662936 | 0.77 | CYP17A1 (0.56) | CYP17A1CYP11B1CYP11B2CYP26A1CYP3A4 | |
| SCHEMBL6362302 | 0.75 | CYP17A1 (0.54) | CYP17A1CYP11B1CYP11B2CYP26A1CYP3A4 | |
| SCHEMBL4054853 | 0.75 | CYP17A1 (0.68) | CYP17A1CYP11B1CYP11B2CYP26A1CYP19A1 | |
| SCHEMBL4046337 | 0.74 | CYP17A1 (0.58) | CYP17A1CYP11B1CYP11B2CYP26A1CYP19A1 | |
| SCHEMBL5565076 | 0.73 | CYP17A1 (0.54) | CYP17A1CYP11B1CYP11B2CYP26A1CYP3A4 | |
| SCHEMBL4046842 | 0.73 | CYP17A1 (0.57) | CYP17A1CYP11B1CYP11B2CYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | MABIRE DOMINIQUE | 2007-05-10 | — | — | US | claimed |
| EP-1037880-B1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-30 | — | — | EP | claimed |
| EP-1037880-B1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | RXRA, RXRB, RXRG | CYP17A1 304/4885CYP11B1 126/4885CYP11B2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.